MP51-04 TUMOUR VOLUME ESTIMATION FROM PREOPERATIVE MEASUREMENT OF PROSTATE VOLUME AND SERUM AND URINE BIOMARKERS.

Abstract

You have accessJournal of UrologyProstate Cancer: Localized V1 Apr 2014MP51-04 TUMOUR VOLUME ESTIMATION FROM PREOPERATIVE MEASUREMENT OF PROSTATE VOLUME AND SERUM AND URINE BIOMARKERS. Mathieu Roumiguie, Léonor Nogueira, Jean Baptiste Beauval, Xavier Gamé, Michel Soulié, Pascal Rischmann, and Bernard Malavaud Mathieu RoumiguieMathieu Roumiguie More articles by this author , Léonor NogueiraLéonor Nogueira More articles by this author , Jean Baptiste BeauvalJean Baptiste Beauval More articles by this author , Xavier GaméXavier Gamé More articles by this author , Michel SouliéMichel Soulié More articles by this author , Pascal RischmannPascal Rischmann More articles by this author , and Bernard MalavaudBernard Malavaud More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1660AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Tumour volume is one major aspect of aggressive prostate cancer a robust relationship between tumour volume and a biomarker would prove a valuable adjunct in the process of recommending active treatment or surveillance. We researched whether tumour volume assessed on radical prostatectomy specimens was correlated to preoperative biomarkers tested in serum or urine. Methods Serum and post DRE urine samples were collected after IRB approval in patients due for radical prostatectomy for localized or locally advanced prostate cancer. Total PSA (Axsym° Abbott), Prostate Health Index that incorporates total PSA, free PSA and p2PSA in its calculation (PHI, Beckmann), PCA3 score (GeneProbe/Hologic°) and T2:ERGa/PSA score (GeneProbe/Hologic°) were obtained preoperatively and correlated to the tumour volume (TV) measured by planimetry on the surgical specimen. Results 124 consecutive patients were recruited. All samples were tested after the procedure to avoid selection bias. Prostate and tumour volumes as well as biomarkers were log-transformed to ensure normality. Prostate volume (Pearson’s r=0.25, p=0.002), total PSA, PHI index, PCA3 and T2:ERGa/PSA scores were significantly correlated with tumour volumes (Fig1). Linear multivariate analysis showed that tumour volume could be approximated with high significance (r2=0.248, p<0.00006) from the linear combination of prostate volume (coefficient 0.89, p<0.001), PHI (0.35, p=0.01) and T2:ERGa/PSA score (0.11, p=0.01) while PCA3 did not add to the model. Conclusions Tumour volume can be estimated with statistical significance from a linear combination of prostate volume and a selection of biomarkers. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e598 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Mathieu Roumiguie More articles by this author Léonor Nogueira More articles by this author Jean Baptiste Beauval More articles by this author Xavier Gamé More articles by this author Michel Soulié More articles by this author Pascal Rischmann More articles by this author Bernard Malavaud More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...